Listed by the USPTO as CHANDRAKUMAR, NIZAL S
Tech Center 1600 • Art Units: 1625 1629 1674
This examiner grants 73% of resolved cases
CHANDRAKUMAR, NIZAL S is associated with Tech Center 1600 and art unit 1625. The profile includes 1794 resolved cases, a 72.6% allowance rate, and a median of 835 days to allowance. The large case volume makes the outcome pattern useful for portfolio planning, and allowance occurs in a majority of recorded matters.
The interview lift is 18.3%, showing a higher observed allowance result for interviewed matters. Practitioners may use that relationship to support interview consideration while continuing to focus on claim language and prior-art distinctions. The leading companies are Revolution Medicines Inc., Beone Medicines I GmbH, and Nicoventures Trading Limited. The leading firms are BakerHostetler, Clark+Elbing LLP - Revolution Medicines, Inc., and FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17836814 | ORAL PRODUCTS WITH REDUCED IRRITATION | Final Rejection | NICOVENTURES TRADING LIMITED |
| 18700643 | METHODS OF TREATING DISEASES ASSOCIATED WITH SENESCENT CELL ACCUMULATION | Final Rejection | University of Florida Research Foundation, Incorporated |
| 18547871 | DEVELOPMENT OF PRMT-TARGETING THERAPY TO ENHANCE EGFR-TARGETING DRUG EFFICACY IN NSCLC | Final Rejection | The Regents of the University of California |
| 18777339 | Benzimidazole Pyridine Derivatives | Non-Final OA | Hoffmann-La Roche Inc. |
| 18604926 | PHARMACEUTICAL COMPOSITIONS COMPRISING APRACLONIDINE FOR OCULAR REDNESS RELIEF | Non-Final OA | ALCON INC. |
| 19106317 | SUBSTITUTED PYRIDOPYRIMIDINONES | Non-Final OA | MIRATI THERAPEUTICS, INC. |
| 18248364 | INHIBITORS OF THE BROMODOMAIN PHD FINGER TRANSCRIPTION FACTOR (BPTF) AS ANTI-CANCER AGENTS | Non-Final OA | Regents of the University of Minnesota |
| 18705232 | PESTICIDALLY ACTIVE PYRIDAZINONE COMPOUNDS | Final Rejection | SYNGENTA CROP PROTECTION AG |
| 18633298 | Metal-Assisted Delayed Fluorescent Emitters Employing Benzo-imidazo-phenanthridine and Analogues | Final Rejection | Arizona Board of Regents on behalf of Arizona State University |
| 18853224 | IMMUNE MODULATORY AGENTS | Non-Final OA | PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
| 18549852 | METHODS FOR TREATING SMALL CELL LUNG CANCER AND OTHER NEUROENDOCRINE CANCERS | Non-Final OA | AstraZeneca AB |
| 18573813 | COMPOUNDS FOR MODULATING MYCOBACTERIUM TUBERCULOSIS RESPONSE | Final Rejection | Rutgers, The State University of New Jersey |
| 18255749 | OIL-IN-WATER EMULSIFIED COMPOSITION | Non-Final OA | KAO CORPORATION |
| 17776922 | METHODS OF INDUCING OR ENHANCING FARNESOID X RECEPTOR (FXR)-MEDIATED TRANSCRIPTIONAL RESPONSE | Non-Final OA | YALE UNIVERSITY |
| 18684747 | CRYSTAL FORMS OF 6-(CYCLOPROPANECARBOXAMIDO)-4-((2-METHOXY-3- (1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3) PYRIDAZINE-3-CARBOXAMIDE | Non-Final OA | Bristol-Myers Squibb Company |
| 18689222 | METHOD FOR PRODUCING COMPOUND | Final Rejection | Mitsubishi Gas Chemical Company, Inc. |
| 18746428 | FORMULATIONS OF T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF | Non-Final OA | Praxis Precision Medicines, Inc. |
| 18603755 | Pyrazolopyridinone Compounds | Non-Final OA | Beigene Switzerland GMBH |
| 18836681 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | Final Rejection | Vertex Pharmaceuticals Incorporated |
| 18569361 | ROS-RESPONSIVE CAPTOPRIL-CINNAMALDEHYDE PRODRUGS AND COMPOSITIONS AND METHODS THEREOF | Non-Final OA | The University of Hong Kong |
| 18788348 | READY-TO-USE BARRIER AND KNOCKDOWN PESTICIDES | Non-Final OA | United Industries Corporation |
| 18671477 | IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | Non-Final OA | Incyte Corporation |
| 18577529 | THE USE OF BETA-HYDROXYBUTYRATES FOR THE TREATMENT OR PREVENTION OF ANEURYSMS AND DISSECTIONS | Non-Final OA | Georgia State University Research Foundation, Inc. |
| 18864033 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | Non-Final OA | Skyhawk Therapeutics, Inc. |
| 17784972 | COMPOUNDS, POLYMERS, DEVICES, AND USES THEREOF | Final Rejection | SIGILON THERAPEUTICS, INC. |
| 17800049 | HETEROCYCLIC DERIVATIVES AS TRMP8 ANTAGONISTS | Non-Final OA | Givaudan SA |
| 18837146 | HETEROCYCLIC GLP-1 AGONISTS | Non-Final OA | Gasherbrum Bio, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy72.6% of resolved applications examined by Nizal S Chandrakumar were allowed (1,794 resolved cases), compared with 51.3% across Art Unit 1625 over the last five years.
This examiner's interview lift is +18.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Nizal S Chandrakumar took 835 days on average from filing to allowance.
Nizal S Chandrakumar examines applications in Art Unit 1625 in Tech Center 1600 (Biotechnology & Pharmaceuticals).